Transcutaneous Mechanical Nerve Stimulation (TMNS) by Vibration in the Treatment of Incontinence

This study has been withdrawn prior to enrollment.
(Failure to include)
Sponsor:
Information provided by:
Copenhagen University Hospital at Herlev
ClinicalTrials.gov Identifier:
NCT00695058
First received: June 9, 2008
Last updated: February 23, 2012
Last verified: February 2012

June 9, 2008
February 23, 2012
August 2008
September 2010   (final data collection date for primary outcome measure)
Diaper test - weight (grams); Micturition diary - The number of involuntary incontinence and normal micturition episodes; Amplitude of vibration (mm) and pressure (cm H2O) in the external sphincter of the urethra [ Time Frame: Before treatment, after treatment and at follow up ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00695058 on ClinicalTrials.gov Archive Site
Validated symptom score (ICI-Q) including: changes in incontinence and micturition patterns; patients' subjective assessment of their symptoms [ Time Frame: before treatment, after treatment and at follow up ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Transcutaneous Mechanical Nerve Stimulation (TMNS) by Vibration in the Treatment of Incontinence
Transcutaneous Mechanical Nerve Stimulation (TMNS) by Vibration in the Treatment of Incontinence

During transcutaneous mechanical nerve stimulation in spinal cord injured men an increase in pressure was observed in the external urethral sphincter along with an increase in bladder capacity. In a subsequent study it was demonstrated that TMNS in women could induce pressure increment of the external urethral sphincter. A pilot study have since shown that after 6 weeks of stimulation 24 out of 33 women suffering from urinary stress incontinence were able to contract their pelvic floor muscles and had become free of symptoms. Another pilot study has shown promising effect on the overactive bladder syndrome.

The present study aims to treat urinary incontinence and includes 3 groups of patients with 40 patients in each group: Women suffering from urinary stress incontinence, women suffering from urge incontinence and men suffering from urinary incontinence after a prostatectomy. A medical vibrator is used and in each group the subjects will be randomized to active treatment or placebo treatment.

In women the stimulation will be performed at the perineum every day for 6 weeks with an amplitude of 2 mm and a frequency of 100 Hz. In men the vibration parameter/location will be determined by the results of a pressure profile study also included. Results will be evaluated on the basis of questionnaires, micturition diaries and diaper tests.

If we are able to demonstrate a significant reduction in the incontinence symptoms in the subjects we asses that vibration can be a way of reestablishing a normal function of the pelvic floor muscles and bladder function in incontinent patients.

Not Provided
Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Subject)
Primary Purpose: Treatment
Urinary Incontinence
Device: Transcutaneous mechanical nerve stimulation by A medical vibrator (FERTI CARE personel, Multicept A/S, Albertslund, Danmark)

A medical vibrator (FERTI CARE personel, Multicept A/S, Albertslund, Denmark) will be used. The stimulation works through a vibrating disc of hard plastic with a diameter of 3.5 cm. The stimulation point will be the perineum in women and the perineum or the frenulum in men.

In the women the stimulation will be performed with a vibration amplitude of 2 mm and a frequency of 100 Hz. In the men the vibration parameter/location will be determined by the results of the new pressure profile studies (aim 3).

A daily stimulation sequence consisting of 10 seconds of stimulation followed by a 10 second pause repeated 10 times will be used through 6 weeks in both the women with stress incontinence and overactive bladder syndrome.

In the 3 groups of patients the subjects will be randomized to either active treatment or placebo treatment. The placebo treatment will be done with a vibration device with an amplitude of 0 mm. Subjects will be randomized by a draw.

  • Experimental: 1
    Women with stress incontinence treated with active TMNS (vibration)
    Intervention: Device: Transcutaneous mechanical nerve stimulation by A medical vibrator (FERTI CARE personel, Multicept A/S, Albertslund, Danmark)
  • Placebo Comparator: 2
    Women with stress incontinence treated with placebo TMNS (vibration)with an amplitude of 0
    Intervention: Device: Transcutaneous mechanical nerve stimulation by A medical vibrator (FERTI CARE personel, Multicept A/S, Albertslund, Danmark)
  • Experimental: 3
    Women with overactive bladder syndrome treated with active TMNS (vibration)
    Intervention: Device: Transcutaneous mechanical nerve stimulation by A medical vibrator (FERTI CARE personel, Multicept A/S, Albertslund, Danmark)
  • Placebo Comparator: 4
    Women with overactive bladder syndrome treated with placebo TMNS (vibration)with an amplitude of 0
    Intervention: Device: Transcutaneous mechanical nerve stimulation by A medical vibrator (FERTI CARE personel, Multicept A/S, Albertslund, Danmark)
  • Experimental: 5
    males who are still incontinent at a minimum of one year after a radical prostatectomy treated with active TMNS (vibration)
    Intervention: Device: Transcutaneous mechanical nerve stimulation by A medical vibrator (FERTI CARE personel, Multicept A/S, Albertslund, Danmark)
  • Placebo Comparator: 6
    males who are still incontinent at a minimum of one year after a radical prostatectomy treated with placebo TMNS (vibration)with an amplitude of 0
    Intervention: Device: Transcutaneous mechanical nerve stimulation by A medical vibrator (FERTI CARE personel, Multicept A/S, Albertslund, Danmark)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Withdrawn
0
September 2010
September 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Women suffering from stress incontinence
  • Women suffering from overactive bladder syndrome
  • Men who are still incontinent at a minimum of one year after a radical prostatectomy

Exclusion Criteria:

  • Pregnant and nursing women will not be included in the study
Both
18 Years and older
Yes
Contact information is only displayed when the study is recruiting subjects
United States,   Denmark
 
NCT00695058
H-B-2007-047
Yes
Mikkel Fode/medical student, Copenhagen University Hospital at Herlev
Copenhagen University Hospital at Herlev
Not Provided
Study Director: Jens R Sonksen, MD, Ph.D Copenhagen University Hospital at Herlev
Copenhagen University Hospital at Herlev
February 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP